AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022. Key results include: Total revenues increased 6% to $6.2...

Related Keywords

United Kingdom ,United States ,Puerto Rico ,Japan ,Japanese ,Americans ,American ,Jessica Akopyan ,Roberta Bradway ,Provention Bio ,Revenue Service ,Amgen ,Tax Court ,American Society Of Clinical Oncology ,Healthy Society ,Research Development ,Astrazeneca ,Therapeutics Inc ,Arrakis Therapeutics Inc ,Teneobio Inc ,Repatha On China National Reimbursement Drug List ,Kyowa Kirin Co Ltd ,Regeneron Pharmaceuticals Inc ,American Academy Of Dermatology Association ,Amgen Foundation Inc ,Plexium Inc ,Beigene Ltd ,Alexion Pharmaceuticals Inc ,American Academy Of Allergy ,Exchange Commission ,Biomedicines Inc ,American Association For Cancer Research ,Amgen Inc ,Company Puerto Rico ,Us Tax Court ,Amgen Foundation ,Amgen Safety Net Foundation ,Internal Revenue Service ,National Reimbursement Drug List ,Average Selling Price ,Sales Detail ,Operating Margin ,Tax Rate ,Operating Expenses ,Rodeo Therapeutics ,Accelerated Stock Repurchase ,Diluted Shares ,Income Taxes ,Quarter Product ,American Academy ,Immunology Annual ,Black Americans ,Dermatology Association ,American Association ,Cancer Research ,American Society ,Clinical Oncology ,Revolution Medicines ,Governance Report Released ,Amgen Safety Net ,Safety Net Foundation ,Wholesale Acquisition ,Janssen Pharmaceutica ,Regeneron Pharmaceuticals ,Alexion Pharmaceuticals ,Accepted Accounting Principles ,Free Cash Flow ,Dow Jones Industrial Average ,Best Workplaces ,Great Place ,Generate Biomedicines ,Arrakis Therapeutics ,Five Prime Therapeutics ,Balance Sheets ,Year Ending December ,Rate Guidance ,